Taisho Pharmaceutical Holdings Co LtdTaisho Pharmaceutical Holdings Co Ltd - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

Scroll down to the bottom of this webpage for potential risks for Taisho Pharmaceutical Holdings Co Ltd based on sector, geography and size. If you work at Taisho Pharmaceutical Holdings Co Ltd and you would like to licence your Sustainability aseessment, please contact us. Full ESG assessment of Taisho Pharmaceutical Holdings Co Ltd can be reached by signing up for free.

Taisho Pharmaceutical Holdings Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.7; made up of an environmental score of 8.0, social score of 8.0 and governance score of 7.0.

SDG Transparency Score for Taisho Pharmaceutical Holdings Co Ltd 
Low
0 - 3
Medium
4 - 6

7.7

High Impact
7 - 10
Last Score Update: 2023-07-01
What drives the score for Taisho Pharmaceutical Holdings Co Ltd 
8.0

Environmental

8.0

Social

7.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
182IPCA Laboratories Ltd
7.8
High
182Concert Pharmaceuticals Inc
7.8
High
187Taisho Pharmaceutical Holdings Co Ltd
7.7
High
187Abbvie Inc
7.7
High
187Biofrontera AG
7.7
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Taisho Pharmaceutical Holdings Co Ltd have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd report the average age of the workforce?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose cybersecurity risks?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd offer flexible work?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd conduct supply chain audits?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose water use targets?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Taisho Pharmaceutical Holdings Co Ltd have a product recall in the last two years?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose incidents of discrimination?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Taisho Pharmaceutical Holdings Co Ltd issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose parental leave metrics?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Taisho Pharmaceutical Holdings Co Ltd involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose its waste policy?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd report according to TCFD requirements?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose energy use targets?

LockedSign up for free to unlock

Does Taisho Pharmaceutical Holdings Co Ltd disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Taisho Pharmaceutical Holdings Co Ltd have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Taisho Pharmaceutical Holdings Co Ltd
These potential risks are based on the size, segment and geographies of the company.

Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.

Sorry!

Failed to process!